Roivant’s mosliciguat cuts pulmonary vascular resistance 56%. Can Phase 3 repeat it?
Pulmovant’s mosliciguat produced unusually large improvements across pulmonary vascular resistance, exercise capacity and cardiac strain in PH-ILD, giving Roivant a strong Phase 2 hand as the much larger PHrontier study tests whether those effects hold.